Biopsy devices market seen reaching $11.2 billion by 2033

By AI, Created 1:05 PM UTC, May 25, 2026, /AGP/ – Persistence Market Research projects the global biopsy devices market will grow from $6.8 billion in 2026 to $11.2 billion by 2033, lifted by rising cancer diagnostics demand and broader use of minimally invasive procedures. North America leads now, while Asia Pacific is emerging as the fastest-growing region.

Why it matters: - Biopsy devices sit at the center of cancer diagnosis and other disease detection workflows. - Rising cancer prevalence and earlier screening programs are increasing demand for tissue sampling tools. - The shift toward minimally invasive procedures is pushing hospitals and diagnostic centers to adopt newer biopsy systems.

What happened: - Persistence Market Research said the global biopsy devices market will be valued at US$ 6.8 billion in 2026. - The market is projected to reach US$ 11.2 billion by 2033. - The forecast implies a 7.4% CAGR from 2026 to 2033. - The report was released May 25, 2026. - The report is available as a free sample.

The details: - Biopsy devices are used to collect tissue samples for diagnosing breast cancer, lung cancer, prostate cancer, gastrointestinal disorders and other diseases. - Needle-based biopsy systems remain the leading segment because of efficiency, affordability and shorter recovery time. - The market also includes vacuum-assisted biopsy systems, biopsy guidance systems and biopsy forceps. - Oncology is the leading application segment because of rising cancer diagnosis rates worldwide. - Hospitals remain the largest end-user segment because of high patient volumes and access to advanced diagnostic tools. - Diagnostic laboratories and specialty clinics are also increasing use of minimally invasive biopsy procedures. - Image-guided biopsy technologies, including ultrasound-guided and MRI-guided systems, are improving procedural precision and treatment planning. - Robotic-assisted procedures are also improving diagnostic accuracy and patient comfort. - Key companies in the market include Becton, Dickinson and Company, Hologic, Medtronic, Boston Scientific, Cook Medical, Cardinal Health, FUJIFILM Holdings and Argon Medical Devices.

Between the lines: - The forecast reflects a broader move in healthcare toward earlier detection, precision medicine and less invasive procedures. - North America remains the largest regional market because of advanced healthcare infrastructure, strong screening programs and favorable reimbursement policies. - The United States is a major growth contributor because of precision diagnostics investment and healthcare modernization. - Asia Pacific is emerging as a fast-growing region as China, India and Japan expand healthcare access and awareness programs. - The report also points to rising healthcare spending and expanding screening coverage as structural growth drivers.

What’s next: - Market growth is expected to stay tied to cancer screening volumes, healthcare investment and adoption of image-guided biopsy systems. - Asia Pacific is expected to gain share as hospital infrastructure and early-diagnosis awareness improve. - Further product innovation is likely to focus on precision, comfort and faster recovery. - More information is available in the company’s announcement and the full report.

The bottom line: - Biopsy devices are on track for steady expansion through 2033 as cancer diagnostics and minimally invasive care become more central to routine medicine.